Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on uniQure (QURE – Research Report) yesterday and set a price target of $21.00. The company’s shares closed yesterday at $6.64.
According to TipRanks, Kluska is a 5-star analyst with an average return of 17.9% and a 36.36% success rate. Kluska covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Soleno Therapeutics, and Disc Medicine.
In addition to Cantor Fitzgerald, uniQure also received a Buy from William Blair’s Sami Corwin in a report issued yesterday. However, on the same day, Wells Fargo maintained a Hold rating on uniQure (NASDAQ: QURE).
See the top stocks recommended by analysts >>
The company has a one-year high of $24.19 and a one-year low of $5.49. Currently, uniQure has an average volume of 1.23M.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure (QURE) Company Description:
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure downgraded to Neutral from Buy at Mizuho
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure announces inducement grants under Nasdaq listing rule
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
